The combination of low cytoplasmic and high nuclear expression of p27 predicts a better prognosis in high-grade astrocytoma

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 597-603

  Hidaka, Toshikazu ^a   Hama, Seiji ^a   Shrestha, Prabin ^a   Saito, Taiichi ^a   Kajiwara, Yoshinori ^a   Yamasaki, Fumiyuki ^a   Sugiyama, Kazuhiko ^a   Kurisu, Kaoru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Cytoplasmic; High grade astrocytoma; Nuclear; p27; Prognosis; Subcellular localization

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P27;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CYTOPLASM; DIAGNOSTIC VALUE; FEMALE; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ASTROCYTOMA; BRAIN NEOPLASMS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 61449216263     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359: 1011-1018, 2002.
2. Sherr CJ: Cancer cell cycles. Science 274: 1672-1627, 1996.
3. DelSal G, Loda M and Pagano M: Cell cycle and cancer: critical events at the G1 restriction point. Crit Rev Oncol 7: 127-142, 1996.
4. Chu IM, Hengst L and Slingerland JM: The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267, 2008.
5. MacLachlan TK, Sang N and Giordano A: Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 5: 127-156, 1995.
6. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A and Santoro M: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kipl) by PKB/Aktmediated phosphorylation in breast cancer. Nat Med 8: 1136-1144, 2002.
7. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G and Giordano A: Frequent loss of expression of the cyclindependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 59: 3790-3794, 1999.
8. Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 6: 4816-4822, 2000.
9. KiP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 154: 119-125, 1999.
10. Baekelandt M, Holm R, Trope CG, Nesland JM and Kristensen GB: Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an irnmunohistochemical study. Clin Cancer Res 5: 2848-2853, 1999.
11. Bai M, Tsanou E, Skyrlas A, Sainis I, Agnantis N and Kanavaros P: Alterations of the p53, Rb and p27 tumor suppressor pathways in diffuse large B-cell lymphomas. Anticancer Res 27: 2345-2352, 2007.
12. Koljonen V, Tukiainen E, Haglund C and Bohling T: Cell cycle control by p21, p27 and p53 in Merkel cell carcinoma. Anticancer Res 26: 2209-2212, 2006.
13. Zafon C, Obiols G, Castellví J, Ramon Y, Cajal S, Baena JA and Mesa J: Expression of p21 (cipl), p27 (kip1), and p16 (Ink4a) cyclin-dependent kinase inhibitors in papillary thyroid carcinoma: Correlation with clinicopathological factors. Endocr Pathol 19: 184-189, 2008.
14. Zolota V, Tsamandas AC, Aroukatos P, Panagiotopoulos V, Maraziotis T, Poulos C and Scopa CD: Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients' outcome. Neurospathology 28: 35-42, 2008.
15. Orend G, Hunter T and Ruoslahti E: Cytoplasmic displacement of cyclin E-cdk2 inhibitor p21/cipl and p27/kipl in anchorage-independent cells. Oncogene 16: 2575-2583, 1998.
16. Shuji O, Takako K and Akiyo O: Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype B. Human Pathology 38: 585-592, 2007.
17. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997.
18. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M and Fuchs CS: Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol 38: 585-592, 2007.
19. Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R, Segato P and Lise M: Low level of p27(Kipl) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 81: 167-176, 2002.
20. Kirla RM, Haapasalo HK, Kalimo H and Salminen EK: Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas. Cancer 97: 644-648, 2003.
21. kiP1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res 11: 632-637, 2005.
22. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M and Loda M: Loss or altered subcellular localization of p27 in Barren's associated adenocarcinoma. Cancer Res 58: 1730-1735, 1998.
23. Florentino M, Altimari A, D'Errico A, Cukor B, Barozzi C, Loda M and Grigioni WF: Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clinical Cancer Res 6: 3966-3972, 2000.
24. kiP1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997.
25. Guo Y, Sklar GN, Borkowski A and Kyprianou N: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3: 2269-2274, 1997.
26. Wang S, Wuu J, Savas L, Patwardhan N and Khan A: The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Hum Pathol 29: 1304-1309, 1998.
27. Firpo EJ, Koff A, Solomon MJ and Roberts JM: Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. Mol Cell Biol 14: 4889-4901, 1994.
28. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee MH, Massague J, Crabtree GR and Roberts JM: Interleukin-2-mediated elimination of p27/Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573, 1994.
29. KiP1 and cyclin D1 in some human breast and colorectal cancers. Proc Natl Acad Sci USA 94: 6380-6385, 1997.
30. Durand B, Gao FB and Raff M: Accumulation of the cyclin dependent kinase inhibitor p27/kipl and the timing of oligodendrocyte differentiation. EMBO J 16: 306-317, 1997.
31. Wei S, Bin B, Fangru W, Chongxiao L and Ying S: P27/Kip1 expression in gliomas and its clinical significance. Chinese-German Clin Oncol 4: 381-383, 2005.
32. Piva R, Cavalla P, Bortolotto S, Cordera S, Richiardi P and Schiffer D: p27/kipl expression in human astrocytic gliomas. Neuroscience Letters 234: 127-130, 1997.
33. Alkarain A, Jordan R and Slingerland J: p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 9: 67-80, 2004.
34. Viglietto G, Motti ML and Fusco A: Understanding p27(kipl) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 1: 394-400, 2002.
35. KiP1. Genes Dev 11: 1464-1478, 1997.
36. KiP1. EMBO J 16: 5334-5344, 1997.
37. Montagnoli A, Fiore F, Eytan E, Roberts JM and Clurman BE: Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13: 1181-1189, 1999.
38. KiP1 is instigated by Jab1. Nature 398: 160-165, 1999.
39. Orend G, Hunter T and Ruoslahti E: Cytoplasmic displacement of cyclin E-cdk2 inhibitor p21/cip1 and p27/kip1 in anchorage-independent cells. Oncogene 16: 2575-2583, 1998.
40. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J and Arteaga CL: PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kipl) at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145-1152, 2002.
41. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E and Slingerland JM: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated Gl arrest. Nat Med 8: 1153-1160, 2002.